CME

Host: James R. Bateman, MD, MPH

Guest: Danya Khoujah, MBBS, MEHP, FACEP, FAAEM

Guest: B. Joy Snider, MD, PhD

Amyloid-related imaging abnormalities (ARIA) represent a critical challenge in the management of Alzheimer's disease (AD), requiring a collaborative, interdisciplinary approach. This program, "Clinical Conundrums: Navigating Case Scenarios in Your Own Practice Setting," offers healthcare professionals concise, case-based microlearning episodes—each approximately 5 minutes long—designed to fit seamlessly into busy schedules. With real-world scenarios and expert-led discussions, this activity provides practical strategies to address diagnostic, monitoring, and therapeutic considerations, equipping participants to optimize patient care and outcomes in their respective fields.

Host: James R. Bateman, MD, MPH

Guest: Jerome A. Barakos, MD

Amyloid-related imaging abnormalities (ARIA) represent a critical challenge in the management of Alzheimer's disease (AD), requiring a collaborative, interdisciplinary approach. This program, "Clinical Conundrums: Navigating Case Scenarios in Your Own Practice Setting," offers healthcare professionals concise, case-based microlearning episodes—each approximately 5 minutes long—designed to fit seamlessly into busy schedules. With real-world scenarios and expert-led discussions, this activity provides practical strategies to address diagnostic, monitoring, and therapeutic considerations, equipping participants to optimize patient care and outcomes in their respective fields.

Host: James R. Bateman, MD, MPH

Guest: B. Joy Snider, MD, PhD

Guest: Jerome A. Barakos, MD

Amyloid-related imaging abnormalities (ARIA) represent a critical challenge in the management of Alzheimer's disease (AD), requiring a collaborative, interdisciplinary approach. This program, "Clinical Conundrums: Navigating Case Scenarios in Your Own Practice Setting," offers healthcare professionals concise, case-based microlearning episodes—each approximately 5 minutes long—designed to fit seamlessly into busy schedules. With real-world scenarios and expert-led discussions, this activity provides practical strategies to address diagnostic, monitoring, and therapeutic considerations, equipping participants to optimize patient care and outcomes in their respective fields.

Host: M. Edip Gurol, MD, MSc

Guest: Robin Novakovic, MD

Guest: Shadi Yaghi, MD

Guest: Jeffrey Weitz, MD

Despite significant efforts to prevent stroke in patients, there remains an unmet need among providers regarding the optimization and benefit-risk profile of anticoagulation therapies. Learn how these therapies may impact the prevention of ischemic stroke and secondary stroke in patients with atrial fibrillation.

Host: Daniel P. Petrylak, MD

Guest: Elizabeth R. Plimack, MD, MS, FASCO

Guest: Evan Y. Yu, MD

This online educational activity, derived from a live satellite symposium at ASCO GU 2025, explores innovative strategies for personalized care in bladder cancer. Participants will gain a deeper understanding of molecular targets and profiling methodologies, review cutting-edge clinical trial evidence, and examine the latest advances in therapy delivery. The program also focuses on creating effective, evidence-based treatment plans and strategies for sequencing molecularly targeted therapies, as well as integrating interprofessional protocols for managing adverse events. This collaborative approach will equip learners with practical insights to enhance treatment outcomes in bladder cancer.

Host: Eric Jonasch, MD

Guest: Brad McGregor, MD

Guest: Ulka Vaishampayan, MBBS

This online educational activity, derived from a live satellite symposium at ASCO GU 2025, explores the latest advances in risk stratification and evidence-based approaches for managing advanced renal cell carcinoma (RCC). Participants will gain a deeper understanding of guideline-driven treatment strategies across RCC histologies and learn strategies for the integration of multidisciplinary approaches to optimize patient care. Emphasis will be placed on shared decision-making and innovative solutions for monitoring and managing treatment-related adverse events. Learners will gain actionable insights for personalizing RCC care and improving patient outcomes.

Host: Nathan A. Boggs, MD

Host: Tracy George, MD

Host: Lindsay Rein, MD

The identification of KIT D816V mutation as a key driver for the expansion and accumulation of neoplastic mast cells in systemic mastocytosis (SM) has significantly improved the diagnosis, subclassification, and management of SM. Moreover, the advent of novel targeted therapies has dramatically changed the treatment landscape. However, challenges persist for community clinicians due to the low prevalence of SM and its vague and wide spectrum of clinical features. Expanded knowledge of the recommended pathology and laboratory evaluation for the diagnosis and subclassification of the disease is needed to shorten delays in diagnosis and delivery of optimal care. Tune in and find out more about the management of SM and the latest clinical evidence and guideline recommendations for the use of tyrosine kinase inhibitors (TKIs) and learn about the role played by pathologists in the identification and diagnosis of SM, which ultimately guides treatment selection.

Host: Nathan A. Boggs, MD

Host: Tracy George, MD

Host: Lindsay Rein, MD

The identification of KIT D816V mutation as a key driver for the expansion and accumulation of neoplastic mast cells in systemic mastocytosis (SM) has significantly improved the diagnosis, subclassification, and management of SM. Moreover, the advent of novel targeted therapies has dramatically changed the treatment landscape. However, challenges persist for community clinicians due to the low prevalence of SM and its vague and wide spectrum of clinical features. Expanded knowledge of the recommended pathology and laboratory evaluation for the diagnosis and subclassification of the disease is needed to shorten delays in diagnosis and delivery of optimal care. Tune in and find out more about the management of SM and the latest clinical evidence and guideline recommendations for the use of tyrosine kinase inhibitors (TKIs) and learn about the role played by pathologists in the identification and diagnosis of SM, which ultimately guides treatment selection.

Host: Nathan A. Boggs, MD

Host: Tracy George, MD

Host: Lindsay Rein, MD

The identification of KIT D816V mutation as a key driver for the expansion and accumulation of neoplastic mast cells in systemic mastocytosis (SM) has significantly improved the diagnosis, subclassification, and management of SM. Moreover, the advent of novel targeted therapies has dramatically changed the treatment landscape. However, challenges persist for community clinicians due to the low prevalence of SM and its vague and wide spectrum of clinical features. Expanded knowledge of the recommended pathology and laboratory evaluation for the diagnosis and subclassification of the disease is needed to shorten delays in diagnosis and delivery of optimal care. Tune in and find out more about the management of SM and the latest clinical evidence and guideline recommendations for the use of tyrosine kinase inhibitors (TKIs) and learn about the role played by pathologists in the identification and diagnosis of SM, which ultimately guides treatment selection.

Host: Nathan A. Boggs, MD

Host: Tracy George, MD

Host: Lindsay Rein, MD

The identification of KIT D816V mutation as a key driver for the expansion and accumulation of neoplastic mast cells in systemic mastocytosis (SM) has significantly improved the diagnosis, subclassification, and management of SM. Moreover, the advent of novel targeted therapies has dramatically changed the treatment landscape. However, challenges persist for community clinicians due to the low prevalence of SM and its vague and wide spectrum of clinical features. Expanded knowledge of the recommended pathology and laboratory evaluation for the diagnosis and subclassification of the disease is needed to shorten delays in diagnosis and delivery of optimal care. Tune in and find out more about the management of SM and the latest clinical evidence and guideline recommendations for the use of tyrosine kinase inhibitors (TKIs) and learn about the role played by pathologists in the identification and diagnosis of SM, which ultimately guides treatment selection.